TNFRSF8 and classic Hodgkin lymphoma: An initial phase I study targeting CD30 with T-cells expressing a CD30-specific chimeric antigen receptor (CAR-T) reported good tolerability but limited clinical responses in 6 patients with relapsed or refractory cHL (of whom 5 had previously received brentuximab vedotin), with an ORR of 33% [66].